



**TTK Healthcare
LIMITED**

TTKH:SEC:SL:081:26

May 30, 2026

**BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001**

Scrip Code: 507747

**National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra East
Mumbai 400 051**

Scrip Code: TTKHLTCARE

Dear Sirs,

**Re : Outcome of the Board Meeting – Disclosure under Regulation 30 of SEBI (LODR)
Regulations, 2015**

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors, in their meeting held today, has, *inter alia*:

- (1) Approved the Audited Financial Results for the Fourth Quarter and the Year ended March 31, 2026.
 - (i) We are attaching herewith a copy of the Audited Financial Results as reviewed by the Audit Committee and approved by the Board of Directors along with the Auditors' Report issued by the Statutory Auditors M/s PKF Sridhar & Santhanam LLP, Chartered Accountants, pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.
 - (ii) We hereby confirm that the said Auditors' Report is with unmodified opinion, a Declaration by the Executive Chairman that the Audit Report is with unmodified opinion is attached herewith.

Please refer Annexure-A.

The said results are also being uploaded on the website of the Company www.ttkhealthcare.com.

- (2) Recommended a Dividend of Rs.10/- per Equity Share (100%) of Rs.10/- each, for the financial year ended March 31, 2026, subject to the approval of the Shareholders at the ensuing 68th Annual General Meeting of the Company and shall be paid within 30 days from the date of AGM.
- (3) Approved the reappointment of Mr. T T Raghunathan (DIN: 00043455) as Executive Chairman (Wholetime Director) of the Company whose current term of appointment expires on October 31, 2026, for a further term of 5 years, with effect from November 01, 2026 and fix his remuneration, based on the recommendations of the Nomination and Remuneration Committee of the Company, subject to the approval of the Shareholders by means of a Special Resolution.

The information required pursuant to the provisions of SEBI Listing Regulations and SEBI circulars are enclosed as **Annexure-B**.

..... 2



TTK Healthcare
LIMITED

2

- (4) Approved the appointment of M/s Geeyes & Co. as the Cost Auditor of the Company for the financial year 2026-27, as per the provisions of Section 148 of the Companies Act, 2013 and the Rules made thereunder and fixed their remuneration and the remuneration fixed is subject to the ratification by the Shareholders of the Company at the ensuing 68th Annual General Meeting of the Company.

The information required pursuant to the provisions of Schedule III of the SEBI (LODR) Regulations, 2015 is enclosed as **Annexure-C**.

- (5) Fixed the date for convening of the 68th Annual General Meeting of the Company on **Friday, July 24, 2026**, through Video Conferencing / Other Audio Visual Means (VC / OAVM).

A brief highlight of the Audited Financial Statements for the year ended March 31, 2026 is enclosed as **Annexure-D**.

We request you to kindly take the above information / documents on record.

The meeting of the Board of Directors was held physically also with the facility of Video Conferencing which commenced at 12 noon and concluded at 01.30 p.m.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(GOWRY A JAISHANKAR)
DGM - Legal & Company Secretary

Encl. : a/a


TTK HEALTHCARE LIMITED

 Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED MARCH 31, 2026
 [Prepared in compliance with the Indian Accounting Standards (Ind AS)]

		(Rs. in lakhs)				
Sl. No.	Particulars	For the Quarter ended			For the Year ended	
		(31/03/2026)	(31/12/2025)	(31/03/2025)	(31/03/2026)	(31/03/2025)
		Audited	Unaudited	Audited	Audited	Audited
I.	Revenue from Operations	21,798.47	20,929.89	19,035.96	85,728.11	80,149.34
II.	Other Income	1,776.81	1,743.34	1,868.87	7,215.00	7,125.49
III.	Total Income (I + II)	23,575.28	22,673.23	20,904.83	92,943.11	87,274.83
IV.	Expenses:					
	(a) Cost of materials consumed	5,149.39	5,138.18	4,957.80	20,049.11	19,533.81
	(b) Purchase of Stock-in-trade	5,329.71	5,395.58	4,811.10	20,305.41	18,694.85
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	141.31	(772.24)	(1,018.40)	(5.65)	(1,337.02)
	(d) Employee benefits expense	4,099.36	4,172.86	3,640.15	16,516.12	15,090.96
	(e) Finance Costs	63.76	68.32	90.47	292.88	332.42
	(f) Depreciation and Amortization Expense	213.81	222.15	216.69	875.95	833.37
	(g) Other Expenses	5,975.81	6,281.80	5,445.03	26,245.54	24,683.92
	Total Expenses (IV)	20,973.15	20,506.65	18,142.84	84,279.36	77,832.31
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	2,602.13	2,166.58	2,761.99	8,663.75	9,442.52
VI.	Exceptional Items (Refer Note 2, 3 & 4 below)	350.42	(757.87)	(586.39)	(407.45)	1,390.66
VII.	Profit / (Loss) before Tax (V + VI)	2,952.55	1,408.71	2,175.60	8,256.30	10,833.18
VIII.	Tax Expense:					
	(1) Current Tax	750.00	440.00	540.00	2,190.00	2,655.00
	(2) Deferred Tax	26.34	(84.55)	20.77	(40.23)	12.49
	(3) Tax relating to earlier years (Refer Note 5 below)	-	-	-	(461.52)	-
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	2,176.21	1,053.26	1,614.83	6,568.05	8,165.69
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-	-
XI.	Tax Expense from Discontinued Operations	-	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	2,176.21	1,053.26	1,614.83	6,568.05	8,165.69
XIV.	Other Comprehensive Income:					
	(A) (i) Items that will not be reclassified subsequently to profit or loss	(190.58)	(36.08)	(658.49)	(146.27)	(402.94)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(26.90)	1.36	95.93	(28.53)	63.21
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV.	Total Comprehensive Income for the period / year (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period / year]	1,958.73	1,018.54	1,052.27	6,393.25	7,825.96
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)				1,09,630.58	1,04,650.36
XVI.	Earnings per Equity Share (For Continuing Operations):					
	(1) Basic (in Rs.)	15.40	7.45	11.43	46.48	57.79
	(2) Diluted (in Rs.)	15.40	7.45	11.43	46.48	57.79
XVII.	Earnings per Equity Share (For Discontinued Operations):					
	(1) Basic (in Rs.)	-	-	-	-	-
	(2) Diluted (in Rs.)	-	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):					
	(1) Basic (in Rs.)	15.40	7.45	11.43	46.48	57.79
	(2) Diluted (in Rs.)	15.40	7.45	11.43	46.48	57.79

Notes:

- (1) The above financial results for the Fourth Quarter and Year ended March 31, 2026 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on May 29, 2026 and approved by the Board of Directors of the Company at its meeting held on May 30, 2026 at the Registered Office of the Company, also with the provision of Video Conferencing facility. The Statutory Auditors have audited the above results and have issued an unmodified opinion.



- (2) On November 21, 2025, the Government of India notified the four Labour Codes, consolidating 29 existing labour laws, and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs. Based on the best information presently available and in line with the guidance issued by the Institute of Chartered Accountants of India, the Company has assessed the incremental impact arising from the change in the definition of wages and, considering its material, regulatory-driven and non-recurring nature, has presented the same as Exceptional items in the Statement of Profit and Loss for the year ended March 31, 2026.
- The incremental impact comprises of Gratuity of Rs.823.02 lakhs and Long-term Compensated Absences of Rs.284.85 lakhs, against which a provision of Rs.350 lakhs created in FY 2020-21 has been adjusted, resulting in a net charge of Rs.757.87 lakhs recognised in the Third Quarter of the current financial year.
- The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits including that of contract workforce.
- The Company is in the process of revising the Wage Structure in FY 2026-27 and would provide appropriate accounting treatment as and when it is finalized.
- (3) The Company has recognised Rs.350.41 lakhs as exceptional income during the fourth quarter of the current year towards GST refund relating to earlier periods, which was received subsequently.
- (4) Exceptional Items pertaining to Previous year:
- (a) During the First Quarter of the previous year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
- (b) During the Fourth Quarter of the previous year, the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
- (5) The tax relating to earlier years represents the tax refund relating to AY 2016-17 & AY 2017-18 received, consequent to completion of assessments.
- (6) The Board has recommended a dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each for the financial year ended March 31, 2026.
- (7) The Company does not have any Subsidiary / Associate / Joint Venture Company(ies) as on December 31, 2025.
- (8) The figures for the Quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to limited review.
- (9) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (10) This statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (11) **Statement of Assets and Liabilities as at March 31, 2026:**

Sl. No.	Particulars	(Rs. in lakhs)	
		As on 31/03/2026 Audited	As on 31/03/2025 Audited
(A)	ASSETS:		
I	Non-Current Assets:		
(a)	Property, Plant and Equipment	6,360.11	6,776.15
(b)	Right of Use Asset	907.17	1,313.74
(c)	Capital Work-in-Progress	136.79	8.28
(d)	Other Intangible Assets	-	-
(e)	Financial Assets		
(i)	Investments	865.56	1,121.82
(ii)	Others Financial Assets	1,397.74	6,990.79
(f)	Non-current Tax Assets (Net)	739.64	895.16
(g)	Deferred Tax Assets (Net)	606.78	595.08
(h)	Other Non-current Assets	70.43	28.47
	Total Non-Current Assets	11,084.22	17,729.49
II	Current Assets:		
(a)	Inventories	10,871.72	10,858.86
(b)	Financial Assets		
(i)	Investments	-	-
(ii)	Trade Receivables	11,066.31	9,052.85
(iii)	Cash and Cash Equivalents	2,188.14	900.64
(iv)	Bank balances other than (iii) above	61,158.78	77,748.36
(v)	Other Financial Assets	34,145.59	10,226.59
(c)	Current Tax Assets (Net)	-	117.27
(d)	Other Current Assets	2,359.49	1,484.61
	Total Current Assets	1,21,790.03	1,10,389.18
	TOTAL ASSETS	1,32,874.25	1,28,118.67



Sl. No.	Particulars	(Rs. in lakhs)	
		As on	As on
		31/03/2026	31/03/2025
		Audited	Audited
(B)	EQUITY AND LIABILITIES:		
(1)	Equity		
(a)	Equity Share Capital	1,413.03	1,413.03
(b)	Other Equity	1,10,072.01	1,05,091.79
	Equity attributable to owners of the Company	1,11,485.04	1,06,504.82
	Total Equity	1,11,485.04	1,06,504.82
(2)	Liabilities		
	Non-current Liabilities:		
(a)	Financial Liabilities:		
(i)	Lease Liabilities	197.92	177.28
(b)	Provisions	567.83	344.26
(c)	Deferred Revenue Income		
	Total Non-current Liabilities	765.75	521.54
	Current Liabilities:		
(a)	Financial Liabilities		
(i)	Borrowings	2,190.39	2,193.51
(ia)	Lease Liabilities	49.48	51.16
(ii)	Trade Payables:		
(A)	Total outstanding dues to Micro Enterprises and Small Enterprises	2,206.82	2,342.17
(B)	Total outstanding dues to creditors other than Micro Enterprises and Small Enterprises	6,923.55	8,341.84
(iii)	Other Financial Liabilities	5,668.35	5,120.16
(b)	Other Current Liabilities	370.15	388.31
(c)	Provisions	2,486.50	2,084.65
(d)	Current Tax Liabilities (Net)	728.22	570.51
	Total Current Liabilities	20,623.46	21,092.31
	TOTAL LIABILITIES	21,389.21	21,613.85
	TOTAL EQUITY AND LIABILITIES	1,32,874.25	1,28,118.67

(12) **Statement of Cash Flow for the year ended 31st March, 2026:**

Particulars	(Rs. in lakhs)	
	For the year ended	For the year ended
	(31/03/2026)	(31/03/2025)
	Audited	Audited
Cash Flow from Operating activities:		
Profit Before tax from operations	8,256.30	10,833.18
Adjustments for:		
Remeasurements of defined benefit plans	139.99	(268.96)
Depreciation and amortisation Expenses	875.95	833.37
Provision for Doubtful Debts	0.76	28.04
Bad debts written off	19.52	32.89
Creditors written back	(27.79)	(45.38)
Interest paid	292.88	332.42
Interest received	(6,924.18)	(6,940.67)
(Profit) / Loss on Sale of Assets	(139.62)	(15.51)
(Profit) / Loss on Sale of Leased Assets	(22.47)	(2,092.63)
Loss on Impairment	-	0.06
Loss of Obsolescence	-	0.06
Dividend income	(10.86)	(10.85)
Un Realised Forex (Gain) / Loss	(14.79)	9.88
Operating Profit before working Capital Changes:	2,445.69	2,695.90
Adjustments for Working Capital changes:		
Inventories	(12.86)	(1,159.88)
Trade receivables	(2,016.92)	(478.01)
Other Receivables	(866.60)	317.80
Trade payables	(1,536.22)	477.48
Other liabilities	1,170.08	530.12
Cash generated from operations:	(816.83)	2,383.41
Less: Direct Taxes Paid	2,031.51	2,780.98
Add: Direct Taxes Received	733.52	-
Net Cash generated from (used in) Operating Activities	(2,114.82)	(397.57)



Particulars	(Rs. in lakhs)	
	For the year ended	For the year ended
	(31/03/2026)	(31/03/2025)
	Audited	Audited
Cash Flow from Investing Activities:		
Purchase of Property, Plant and Equipment, Other Intangible Assets and Capital advances	(580.23)	(1,283.98)
Proceeds from the sale of Property, Plant and Equipment and Other Intangible Assets (other than Right of Use Asset)	118.37	122.92
Proceeds from the sale of Right of Use Asset	102.96	2,206.65
Investment in Equity Shares	(30.00)	-
Investments in Bank deposits (Net)	(1,214.93)	(5,567.21)
Interest received	6,750.88	6,521.11
Dividend Received	10.86	10.85
Net Cash generated from (used in) investing Activities	5,157.91	2,010.34
Cash Flow from Financing Activities:		
Borrowings (Net of repayment)	(3.12)	46.21
Principal repayment of Lease Liabilities	(56.34)	(62.13)
Interest Paid on other than Lease Activity	(256.10)	(365.22)
Interest Paid on Lease Activity	(27.00)	(13.89)
Dividend Paid	(1,413.03)	(1,413.03)
Net Cash generated from (used in) Financing Activities	(1,755.59)	(1,808.06)
Net Increase / (Decrease) in Cash and Cash Equivalents	1,287.50	(195.29)
Cash and Cash Equivalents as at the beginning of the year	900.64	1,095.93
Total	2,188.14	900.64
Cash and Cash Equivalents as at the end of the year (as per Balance Sheet)	2,188.14	900.64

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : May 30, 2026



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

**SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES
 FOR THE FOURTH QUARTER AND YEAR ENDED MARCH 31, 2026**

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Year ended	
		(31/03/2026)	(31/12/2025)	(31/03/2025)	(31/03/2026)	(31/03/2025)
		Audited	Unaudited	Audited	Audited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)					
	(a) Animal Welfare	3,581.35	3,791.21	3,060.10	14,108.37	12,637.05
	(b) Consumer Products	5,396.55	5,541.05	5,290.85	24,127.82	24,492.52
	(c) Medical Devices	2,693.75	2,554.14	2,259.66	10,691.69	9,014.53
	(d) Protective Devices	6,098.47	5,398.58	4,759.60	21,650.81	20,663.87
	(e) Foods	4,019.26	3,633.80	3,653.95	15,109.96	13,305.98
	(f) Others	9.09	11.11	11.80	39.46	35.39
	Total	21,798.47	20,929.89	19,035.96	85,728.11	80,149.34
	Less : Inter Segment Revenue	-	-	-	-	-
	Net Sales / Income from Operations	21,798.47	20,929.89	19,035.96	85,728.11	80,149.34
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]					
	(a) Animal Welfare	245.56	395.54	320.37	1,192.15	1,098.52
	(b) Consumer Products	528.78	225.18	285.43	1,835.15	2,345.32
	(c) Medical Devices	349.26	492.50	642.65	2,254.24	2,215.05
	(d) Protective Devices	625.16	(110.23)	631.76	(1,054.25)	252.62
	(e) Foods	329.24	339.78	132.96	1,343.29	449.89
	(f) Others	8.91	12.69	(9.90)	40.16	14.70
	Total	2,086.91	1,355.46	2,003.27	5,610.74	6,376.10
	Less : Finance Cost	63.76	68.32	90.47	292.88	332.42
	Less : Unallocable Expenses (Net of Unallocable Income)	(929.40)	(121.57)	(262.80)	(2,938.44)	(4,789.50)
	Total Profit (+) / Loss (-) before tax	2,952.55	1,408.71	2,175.60	8,256.30	10,833.18
		As on 31/03/2026	As on 31/12/2025	As on 31/03/2025	As on 31/03/2026	As on 31/03/2025
3.	Segment Assets:					
	(a) Animal Welfare	4,396.46	4,659.50	3,859.37	4,396.46	3,859.37
	(b) Consumer Products	5,048.95	4,198.40	4,521.96	5,048.95	4,521.96
	(c) Medical Devices	8,189.43	8,413.59	7,135.97	8,189.43	7,135.97
	(d) Protective Devices	14,805.10	13,136.93	13,715.76	14,805.10	13,715.76
	(e) Foods	5,254.91	6,000.53	6,931.64	5,254.91	6,931.64
	(f) Others	299.17	295.57	289.73	299.17	289.73
	Total	37,994.02	36,704.52	36,454.43	37,994.02	36,454.43
	Unallocated	94,880.23	94,560.51	91,664.24	94,880.23	91,664.24
	Total Assets	1,32,874.25	1,31,265.03	1,28,118.67	1,32,874.25	1,28,118.67



		As on 31/03/2026	As on 31/12/2025	As on 31/03/2025	As on 31/03/2026	As on 31/03/2025
4.	Segment Liabilities:					
(a)	Animal Welfare	2,923.98	3,112.05	2,920.65	2,923.98	2,920.65
(b)	Consumer Products	5,144.44	4,847.86	6,568.01	5,144.44	6,568.01
(c)	Medical Devices	1,492.39	1,623.81	1,367.74	1,492.39	1,367.74
(d)	Protective Devices	4,629.67	3,672.34	4,324.52	4,629.67	4,324.52
(e)	Foods	1,508.26	1,659.86	1,665.60	1,508.26	1,665.60
(f)	Others	142.14	133.47	136.92	142.14	136.92
	Total	15,840.88	15,049.39	16,983.44	15,840.88	16,983.44
	Unallocated	5,548.33	6,689.34	4,630.41	5,548.33	4,630.41
	Total Liabilities	21,389.21	21,738.73	21,613.85	21,389.21	21,613.85

Notes:

- (1) Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
- (2) Details of products included in each of the Segments are as below :
 - ❖ Animal Welfare comprise products for Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
- (3) The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
- (4) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place : Chennai
Date : May 30, 2026


T. RAGHUNATHAN
Executive Chairman



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED MARCH 31, 2026**(Rs. in lakhs)**

Sl. No.	Particulars	For the Quarter ended			For the Year ended	
		(31/03/2026)	(31/12/2025)	(31/03/2025)	(31/03/2026)	(31/03/2025)
		Audited	Unaudited	Audited	Audited	Audited
1.	Total income from Operations	21,798.47	20,929.89	19,035.96	85,728.11	80,149.34
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	2,602.13	2,166.58	2,761.99	8,663.75	9,442.52
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	2,952.55	1,408.71	2,175.60	8,256.30	10,833.18
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	2,176.21	1,053.26	1,614.83	6,568.05	8,165.69
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,958.73	1,018.54	1,052.27	6,393.25	7,825.96
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	1,09,630.58	1,04,650.36
8.	Earnings per share (of Rs.10/- each) (for Continuing and Discontinued Operations)					
	(a) Basic (in Rs.)	15.40	7.45	11.43	46.48	57.79
	(b) Diluted (in Rs.)	15.40	7.45	11.43	46.48	57.79

Notes:

- (1) The above is an extract of the detailed Statement of Audited Financial Results for the Fourth Quarter and Year ended March 31, 2026, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Fourth Quarter and Year ended March 31, 2026 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) These financial results have been reviewed by the Audit Committee at its meeting held on May 29, 2026 and approved by the Board of Directors of the Company at its meeting held on May 30, 2026 at the Registered Office of the Company, also with the provision of Video Conferencing facility. The Statutory Auditors have audited the above results and have issued an unmodified opinion.
- (4) On November 21, 2025, the Government of India notified the four Labour Codes, consolidating 29 existing labour laws, and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs. Based on the best information presently available and in line with the guidance issued by the Institute of Chartered Accountants of India, the Company has assessed the incremental impact arising from the change in the definition of wages and, considering its material, regulatory-driven and non-recurring nature, has presented the same as Exceptional items in the Statement of Profit and Loss for the year ended March 31, 2026.

The incremental impact comprises of Gratuity of Rs.823.02 lakhs and Long-term Compensated Absences of Rs.284.85 lakhs, against which a provision of Rs.350 lakhs created in FY 2020-21 has been adjusted, resulting in a net charge of Rs.757.87 lakhs recognised in the Third Quarter of the current financial year.

The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits including that of contract workforce.

The Company is in the process of revising the Wage Structure in FY 2026-27 and would provide appropriate accounting treatment as and when it is finalized.
- (5) The Company has recognized Rs.350.41 lakhs as exceptional income during the fourth quarter of the current year towards GST refund relating to earlier periods, which was received subsequently.
- (6) Exceptional Items pertaining to Previous year:
 - (a) During the First Quarter of the previous year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
 - (b) During the Fourth Quarter of the previous year, the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
- (7) The tax relating to earlier years represents the tax refund relating to AY 2016-17 & AY 2017-18 received, consequent to completion of assessments.
- (8) The Board has recommended a dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each for the financial year ended March 31, 2026.

- (9) The Company does not have any Subsidiary / Associate / Joint Venture Company(ies) as on December 31, 2025.
- (10) The figures for the Quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to limited review.
- (11) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place : Chennai
Date : May 30, 2026


T T RAGHUNATHAN
Executive Chairman

Independent Auditors' Report on the financial results

To

The Board of Directors of TTK Healthcare Limited

Opinion

1. We have audited the accompanying Financial Results of TTK Healthcare Limited ("the Company"), for the quarter and year ended 31st March 2026 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the statement:
 - a) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, in this regard;
 - b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the company for the quarter and year ended 31st March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Financial Results

4. This Statement has been prepared on the basis of the audited financial statements for the year ended March 31, 2026.

The Company's Board of Directors are responsible for the preparation and presentation of these Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2026 in accordance with Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with



Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

6. Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.
7. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Management and the Board of Directors' use of



the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
8. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
 9. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

10. Attention is drawn to the fact that the figures for the quarter ended 31st March 2026 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us. Our opinion is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**
Chartered Accountants
Firm's Registration No. 003990S/S200018



Devi P
Partner
Membership No 223137

Place: Chennai

Date: 30-05-2026

UDIN: 26223137YYEZTW6598



**TTK Healthcare
LIMITED**

May 30, 2026

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra East
Mumbai 400 051

Scrip Code: 507747

Scrip Code: TTKHLTCARE

Dear Sirs,

Re : Declaration relating to the Unmodified Opinion by the Statutory Auditors on the Audited Financial Statements for the Fourth Quarter and Year ended March 31, 2026, in accordance with Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015

We hereby declare that the Statutory Auditors of the Company have given their **Unmodified Opinion** on the Audited Financial Statements of the Company for the Fourth Quarter and Year ended March 31, 2026.

Please take the above declaration on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited


(T T RAGHUNATHAN)
Executive Chairman



**TTK Healthcare
LIMITED**

ANNEXURE - B

Disclosure of Information pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circulars

Name of the Director / Key Managerial Personnel	Mr T T Raghunathan
Director Identification Number (DIN) / Membership No.	00043455
Reason for change viz. appointment, resignation, removal, death or otherwise.	Reappointed as Executive Chairman w.e.f. November 01, 2026 for a period of 5 years.
Date of appointment / cessation (as applicable) and term of appointment	November 01, 2026
Brief Resume, Qualification, Experience and Nature of Expertise in specific functional areas	<ul style="list-style-type: none">• Commerce Graduate.• Chairman of the TTK Group of Companies.• Has been on the Board of the Company since 1998.• Has vast Industrial experience spanning over more than four decades.• His areas of expertise include Sales, Marketing & Distribution, Consumer Behaviour, Business Promotion & Strategy, Joint Venture Relations and General Management
Disclosure of Relationship with other Directors and Key Managerial Personnel of the Company	He is the Uncle of Dr T T Mukund, Director of the Company.
Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with Exchange Circular dated June 20, 2018 (Affirmation that the person proposed to be appointed as Director is not debarred from holding the office by virtue of any SEBI Order or any other authority)	We hereby confirm that Mr T T Raghunathan is not debarred from holding the office of Executive Chairman (Wholetime Director) by any SEBI order or any other such authority.
Affirmation that the Director being appointed is not disqualified from holding the office of director pursuant to provisions of Section 164 of the Companies Act, 2013	We hereby confirm that Mr T T Raghunathan is not debarred from holding the office of Executive Chairman (Wholetime Director) pursuant to provisions of Section 164 of the Companies Act, 2013



**TTK Healthcare
LIMITED**

ANNEXURE - C

Details of Appointment

Nature of the Person / Firm	M/s Geeyes & Co.
Designation	Cost Auditor
Reason for change viz. appointment, resignation, removal, death or otherwise.	Appointment
Date of appointment / cessation (as applicable) and terms of appointment	May 30, 2026, for a term of one year. (FY 2026-27)
Brief Profile	<p>The firm Geeyes & Co., established in the year 1994, have rich experience in Industry, Consulting and Management Systems Audits, Cost Audits, and Excellence Assessments. They are Cost Auditors for many companies across several industries. Their areas of specialization and interest include Corporate Strategy, Sustainability, Business Excellence, Total Cost Management, Enterprise Risk Management, Corporate Governance, Project Management, Energy & Environmental Management and Supply Chain Management.</p> <p>The Partners of the firm are Mr. S. Srinivasan, Mr. R. Anantharaman and Mr. Manivannan R. Rajan.</p>
Disclosure of Relationship with Directors	NIL



**TTK Healthcare
LIMITED**

ANNEXURE-D

**HIGHLIGHTS OF THE AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED MARCH 31, 2026**

		(Rs. in lakhs)	
		2025-26	2024-25
Revenue from Operations		85,728.11	80,149.34
Other Income		7,215.00	7,125.49
Total Income		92,943.11	87,274.83
Cost of Materials Consumed		40,348.87	36,891.64
Employee Benefits Expense		16,516.12	15,090.96
Other Expenses		26,245.54	24,683.92
Profit before Finance Cost, Depreciation, Exceptional Items and Tax		9,832.58	10,608.31
Finance Cost		292.88	332.42
Depreciation		875.95	833.37
Profit before Exceptional Items and Tax		8,663.75	9,442.52
Exceptional Items: Profit on sale of Land / Loss on write-off of Inventories		(407.45)	1390.66
Profit before Tax		8,256.30	10,833.18
Less:	Tax Expense		
	Current Tax	2,190.00	2,655.00
	Tax relating to earlier years	(461.52)	-
	Deferred Tax	(40.23)	12.49
Profit after Tax		6,568.05	8,165.69